-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Bp5pSS7cEta/+w8Od3uGogaYyn7X5U92T1rbOMn0EnOsB7apsGgZT3tBm5AAQZN1 l4X6UVCLCBoSxpZCtmFZqQ== 0001021408-02-012378.txt : 20021009 0001021408-02-012378.hdr.sgml : 20021009 20021009165351 ACCESSION NUMBER: 0001021408-02-012378 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20020926 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20021009 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MOLICHEM MEDICINES INC CENTRAL INDEX KEY: 0001143932 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330820923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-64430 FILM NUMBER: 02785340 BUSINESS ADDRESS: STREET 1: 207 SOUTH ELLIOT RD PMB 231 CITY: CHAPEL HILL STATE: NC ZIP: 27514 BUSINESS PHONE: 9199602750 MAIL ADDRESS: STREET 1: 207 SOUTH ELLIOT RD PMB 231 CITY: CHAPEL HILL STATE: NC ZIP: 27514 8-K 1 d8k.htm FORM 8-K FORM 8-K
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): September 26, 2002
 
MOLICHEM MEDICINES, INC.
(Exact name of Company as specified in its charter)
 
Delaware
(State or other jurisdiction of incorporation)
 
 
 
333-64430
  
330820923
(Commission file Number)
  
(IRS Employer ID Number)
 
100 Europa Drive, Suite 421, Chapel Hill, North Carolina
  
27517-2389
(Address of principal executive offices)
  
(Zip Code)
 
Company’s telephone number, including area code 919-960-0217
 

 
Item 5.    Other Events and Regulation D Disclosure.
 
On September 26, 2002, MoliChem issued a press release. A copy of the press release is being furnished as Exhibit 99.1 MoliChem regards any information provided in the press release to be current and accurate only as of the date of the press release and specifically disclaims any duty to update such information unless it is necessary to do so in accordance with applicable law.
 
Item 7.    Financial Statements, Pro Forma Financial Information and Exhibits.
 
(c)  Exhibits.
 
Exhibit
No.
   
Description
99.1
   
Press Release, dated September 26, 2002

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
MOLICHEM MEDICINES, INC.
/s/    LUIS MOLINA        
Luis Molina, Ph.D.,
Chief Executive Officer
 
Date:    September 26, 2002

 
INDEX TO EXHIBITS
 
Exhibit
No.
   
Description
99.1
   
Press Release, dated September 26, 2002
 
 EX-99.1 3 dex991.htm PRESS RELEASE PRESS RELEASE
Exhibit 99.1
 
FOR IMMEDIATE RELEASE:
 
Data on experimental Cystic Fibrosis treatment to be presented at the
North American Cystic Fibrosis Conference October 3-6, 2002
 
Compound under development by MoliChem Medicines and InterMune
 
CHAPEL HILL, N.C. and BRISBANE, CA, September 26, 2002. Clinical trial data on Moli1901, a compound under development by MoliChem Medicines Inc. (MLCM) and InterMune Inc. (ITMN), will be presented at the Sixteenth Annual North American Cystic Fibrosis Conference in New Orleans, Oct. 3-6. Moli1901 is a 19 amino acid peptide under development for the treatment of cystic fibrosis (CF), a genetic disease characterized in the lung by abnormal chloride and water transport which leads to abnormal mucus composition, inflammation, infections and fibrosis.
 
Pamela Zeitlin, MD, of the Department of Pediatrics at Johns Hopkins School of Medicine in Baltimore will present “Moli1901: Novel Activator of Alternative Chloride Channels” during a symposium on activation of chloride transport in CF airways on October 6. Dr. Zeitlin will also present a poster entitled “A Safety and Pharmacokinetic Assessment of Inhaled Administration of Moli1901 in Cystic Fibrosis Patients” on October 5.
 
The data from both presentations cover the pharmacology and safety of a single dose of Moli1901 at four concentrations in 16 healthy participants and 16 CF patients.
 
In addition, Bonnie Ramsey, MD, from the University of Washington, Seattle, will review the Moli1901 development program during the plenary session on October 6 entitled “Developing Better Therapies for Patients with CF: 2002 Progress Report”.
 
About MoliChem
 
MoliChem Medicines, Inc. is an early stage pharmaceutical company focused on the discovery, development, and marketing of products for the treatment of serious respiratory and related conditions. MoliChem’s lead product candidate, Moli1901, is currently in clinical trials in the United States for the treatment of cystic fibrosis.

 
About InterMune
 
InterMune is a commercially driven biopharmaceutical company focused on the marketing, development and applied research of life-saving therapies for pulmonary disease, infectious disease and cancer. For additional information about InterMune, please visit www.intermune.com.
 
For Further Information on MoliChem Contact:
 
Investor contact: Gilles Cloutier Ph.D., Chief Business Officer, 919.960.0217 or gilles@molichem.com
 
Media contact: Jennifer McMillan 919.929.7409 or jennifer@jmcmillaninc.com
 
For Further Information on InterMune Contact:
 
Investor contact: Myesha Edwards, 415.466.2242 or ir@intermune.com
 
Media contact: Jim Weiss, 415.362.5018 or weisscomm@earthlink.net
-----END PRIVACY-ENHANCED MESSAGE-----